Most bioactive peptides are generated by proteolytic cleavage of large precursor proteins
followed by storage in secretory vesicles from where they are released upon cell stimulation …

Covering: 1995 to 2010 Anticonvulsant neuropeptides are best known for their ability to
suppress seizures and modulate pain pathways. Galanin, neuropeptide Y, somatostatin …

Innovative approach to drug design that's more likely to result in an approvable drug product
Retrometabolic drug design incorporates two distinct drug design approaches to obtain soft …

The pharmaceutical potential of natural analgesic peptides is mainly hampered by their
inability to cross the blood–brain barrier, BBB. Increasing peptide–cell membrane affinity …

The endogenous peptide kyotorphin (KTP) has been extensively studied since it was
discovered in 1979. The dipeptide is distributed unevenly over the brain but the majority is …

Tyrosine-arginine (kyotorphin), an opioid analgesic dipeptide, was discovered more than 40
years ago in 1979. The evidence accumulated during this period has established the …

Retrometabolic drug design (RMDD) approaches are systematic methodologies aimed to
design safe compounds with an improved therapeutic index. RMDDs thoroughly integrate …

The established decrease in the level of endogenous kyotorphin (KTP) into the
cerebrospinal fluid of patients with an advanced stage of Alzheimer's disease (AD) and the …

Chronic brain ischemia is a prominent risk factor for neurological dysfunction and
progression for dementias, including Alzheimer's disease (AD). In rats, permanent bilateral …

In Alzheimer's disease (AD), besides the characteristic deterioration of memory, studies also
point to a higher pain tolerance in spite of sensibility preservation. A change in the normal …